Skip to main content
. 2019 Jul 24;9:667. doi: 10.3389/fonc.2019.00667

Figure 3.

Figure 3

Comparison of clinical risk with the risk classification by the BCT score or Oncotype DX RS. Proportion of patients within each risk group according to clinical risk assessment, BCT score, or RS in (A) all patients (n = 771), (B) lymph node-negative (LN-) patients (n = 619), and (C) lymph node-positive (LN+) patients (n = 152). Clinical risk was determined using the modified Adjuvant! Online, as reported in the MINDACT trial. Risk classification by the RS was based on the recurrence score ranges used in the TAILORx.